Strong Revenue and EBITDA Growth
Total constant currency revenue growth of 16% and adjusted EBITDA growth of 39% year-over-year, reflecting strong financial performance.
Stent Graft and On-X Valves as Growth Drivers
Stent graft revenues grew 31% and On-X valve revenues grew 23% year-over-year on a constant currency basis, acting as significant growth engines for the company.
New Clinical Data and Reimbursement Updates
Positive clinical data presented at EX for AMDS and establishment of the approved DRG-209 reimbursement code, enhancing the value proposition for AMDS.
Expansion into New Facilities
Entered into two real estate agreements to expand On-X operational footprint in Austin, Texas, to support future growth.
Pipeline and Market Opportunities
Robust pipeline expected to unlock approximately $1 billion of incremental market opportunity over the next 5-plus years.